Isoxsuprine Hydrochloride

# Isoxsuprine hydrochloride ## Overview - **Classification**: Peripheral vasodilator, beta-adrenergic agonist - **Mechanism**: Directly relaxes vascular smooth muscle, primarily in peripheral and cerebral arteries, via beta-adrenergic agonism. ## Primary Indications 1. **Peripheral Vascular Disease** - Symptomatic relief of conditions like arteriosclerosis obliterans, Buerger's disease, Raynaud's disease. 2. **Cerebrovascular Insufficiency** - Management of symptoms associated with reduced blood flow to the brain. ## Adult Dosing ### Standard Dosing **Peripheral Vascular Disease / Cerebrovascular Insufficiency** - **Dose**: **10 mg** to **20 mg** - **Frequency**: Two to four times daily (BID to QID) - **Route**: Oral - **Maximum Dose**: **80 mg/day** (typically 20 mg QID) ### Dose Adjustments - **Renal Impairment**: Use with caution. No specific dose adjustments are well-established. Monitor for exaggerated hypotensive effects. - **Hepatic Impairment**: Use with caution. No specific dose adjustments are well-established. - **Elderly Patients**: Start with lower doses (e.g., **10 mg BID**) and titrate slowly due to increased sensitivity to hypotensive effects. Monitor closely for dizziness and falls. ## Pediatric Dosing ### Neonates (0-28 days) - No established dosing. - **Special Notes**: Not recommended for use in neonates. Safety and efficacy are not established. ### Infants (1-12 months) - No established dosing. - **Special Notes**: Not recommended for use in infants. Safety and efficacy are not established. ### Children (1-12 years) - No established dosing. - **Special Notes**: Not recommended for use in children. Safety and efficacy are not established. ### Adolescents (13-18 years) - No established dosing. - **Special Notes**: Use is generally not recommended in this age group for its approved indications. If considered, adult dosing may be cautiously approached after thorough risk/benefit assessment, but not routinely indicated. ## Safety Information ### Contraindications - **Absolute**: Recent arterial hemorrhage - **Absolute**: Severe hypotension - **Absolute**: Acute coronary thrombosis - **Absolute**: Active bleeding disorders ### Common Adverse Effects - **Common (1-10%)**: Dizziness, lightheadedness, nausea, vomiting - **Common (1-10%)**: Tachycardia, palpitations, hypotension - **Common (1-10%)**: Flushing, rash - **Serious but Rare**: Severe hypotension leading to syncope ### Key Drug Interactions - **Antihypertensives**: Additive hypotensive effects. Monitor blood pressure closely. - **Other Vasodilators**: Increased risk of hypotension. Concurrent use requires caution. ## Monitoring & Follow-up - **Before Treatment**: Baseline blood pressure (BP) and heart rate (HR). - **During Treatment**: Monitor BP and HR regularly, especially during initial titration. - **Clinical Signs**: Assess for symptomatic improvement or worsening of peripheral/cerebrovascular symptoms. Watch for signs of orthostatic hypotension (dizziness upon standing). ## Clinical Pearls - 💡 **Tip 1**: Advise patients to change positions slowly (e.g., sit up slowly) to minimize orthostatic hypotension. - 💡 **Tip 2**: Take with food or milk if gastrointestinal upset occurs. - 💡 **Tip 3**: This drug is typically not a first-line treatment for its indications and may have limited efficacy compared to other interventions. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.